Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Colorcon
UBS
Federal Trade Commission
Queensland Health
Express Scripts
Accenture
Cipla
AstraZeneca

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,221,633

« Back to Dashboard

Summary for Patent: 6,221,633
Title: Insulin derivatives having a rapid onset of action
Abstract:The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.
Inventor(s): Ertl; Johann (Bremthal, DE), Habermann; Paul (Eppstein, DE), Geisen; Karl (Frankfurt, DE), Seipke; Gerhard (Hofheim, DE)
Assignee: Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)
Application Number:09/099,307
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use; Formulation;

Drugs Protected by US Patent 6,221,633

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021629-001 Apr 16, 2004 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS ➤ Try a Free Trial
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021629-002 Dec 20, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS ➤ Try a Free Trial
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,221,633

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 26 167Jun 20, 1997

International Family Members for US Patent 6,221,633

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel 125006 ➤ Try a Free Trial
Japan H119291 ➤ Try a Free Trial
Luxembourg 91138 ➤ Try a Free Trial
Japan 3676573 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Harvard Business School
Accenture
Federal Trade Commission
AstraZeneca
Fish and Richardson
US Department of Justice
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.